AstraZeneca Could Seek New Indication For Iressa In Europe
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
AstraZeneca Iressa European Marketing Authorization Application withdrawn following the non-small cell lung cancer therapy’s failure to show a survival benefit in recent study. FDA is expected to provide an update on the status of gefitinib’s Subpart H approval in January or February
You may also be interested in...
AstraZeneca’s Iressa Produces Effect In Subpopulation, ASCO Data Show
Results of an initial Phase II study aimed at identifying responders to AstraZeneca's non-small cell lung cancer agent Iressa suggest further research could support approval in a subpopulation, researchers said at the recent American Society of Clinical Oncology meeting in Orlando, Fla
Symbicort NDA On-Track, Exanta Decision Set For Second-Half – AstraZeneca
AstraZeneca will submit additional data for Symbicort inhalation delivery device. Hold-up comes in wake of setbacks for Iressa, Exanta and Crestor